Saneca Pharma secures Menarini Group contract
News Nov 10, 2016
Saneca Pharma has secured an agreement with Italian pharmaceutical company Menarini Group to deliver controlled release pellets for one of its products. As part of the five-year supply agreement, Saneca Pharma will be investing in its facility in Hlohovec, Slovakia, to increase the scale at which it can perform wurster coating of the pellets. The pellets are made by extrusion spheronisation.
The CDMO’s technology will be used to produce enteric coated pellets aimed at preventing dissolution in the stomach, while allowing dissolution in the small intestine. Commenting on the new contract, Anthony Sheehan, CEO at Saneca Pharma said: “We are pleased to be able to offer Menarini a responsive solution to help ensure the long term viability of its product.
“At Saneca Pharma, we have the breadth of technologies and expertise to handle challenging and complex pharmaceutical development and manufacturing projects. This new contract is just one example of how we can assist drug developers and manufacturers with specialist techniques to improve drug efficiency, delivery and patient compliance.”
Before securing the contract, Saneca Pharma demonstrated its pellet manufacturing capabilities to Menarini at a small scale using 100kg batch sizes. Following the investment at its plant, the CDMO will be able to handle significantly larger batch sizes. Francesco Nuzzolo, corporate director of manufacturing at Menarini Group said: “Saneca Pharma is the ideal partner for our pellet manufacturing needs as the team possess the experience along with the technology to successfully support us for these supplies.
“Saneca’s experts were extremely responsive and flexible from the outset of our relationship, demonstrating that they could manufacture enteric coated pellets in a cost-effective manner. We look forward to a successful, long-term partnership.” Based in western Slovakia, with close proximity to Vienna, Saneca Pharma develops and manufactures a variety of finished dosage forms, with strong capabilities in solids and semi-solids and specialist expertise in the development of opiate APIs and final dosage forms from farm to pharmacy.
Saneca Pharma has a proud’ big pharma’ heritage and combines a strong track record of consistent supply and stringent quality standards, with an impressive breadth of services, technical agility and dedicated experts to deliver responsive solutions.
Source: Story from Saneca Pharma. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018